共 7 条
[1]
Discovery and characterization of COVA322; a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases[J] Michela Silacci;Wibke Lembke;Richard Woods;Isabella Attinger-Toller;Nadja Baenziger-Tobler;Sarah Batey;Roger Santimaria;Ulrike von der Bey;Susann Koenig-Friedrich;Wenjuan Zha;Bernd Schlereth;Mathias Locher;Julian Bertschinger;Dragan Grabulovski mAbs 2016,
[2]
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized; Placebo‐Controlled Phase III Trial[J] Arthur Kavanaugh;Lluís Puig;Alice B. Gottlieb;Christopher Ritchlin;Shu Li;Yuhua Wang;Alan M. Mendelsohn;Michael Song;Yaowei Zhu;Proton Rahman;Iain B. McInnes; Arthritis Care & Research 2015,
[3]
Tildrakizumab ( MK ‐3222); an anti‐interleukin‐23p19 monoclonal antibody; improves psoriasis in a phase IIb randomized placebo‐controlled trial[J] K. Papp;D. Tha?i;K. Reich;E. Riedl;R.G. Langley;J.G. Krueger;A.B. Gottlieb;H. Nakagawa;E.P. Bowman;A. Mehta;Q. Li;Y. Zhou;R. Shames Br J Dermatol 2015,
[4]
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR; a randomized controlled trial[J] Diamant Tha?i;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai;Francisco Vanaclocha;Külli Kingo;Michael Ziv;Andreas Pinter;Sophie Hugot;Ruquan You;Marina Milutinovic Journal of the American Academy of Dermatology 2015,
[5]
Ixekizumab for treatment of psoriasis[J] Beatrice Dyring-Andersen;Lone Skov;Claus Zachariae Expert Review of Clinical Immunology 2015,
[6]
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis[J] Kim Papp;Alan Menter;Bruce Strober;Greg Kricorian;Elizabeth H.Z. Thompson;Cassandra E. Milmont;Ajay Nirula;Paul Klekotka Journal of the American Academy of Dermatology 2015,
[7]
Brodalumab; an Anti-IL17RA Monoclonal Antibody; in Psoriatic Arthritis[J] Philip J. Mease;Mark C. Genovese;Maria W. Greenwald;Christopher T. Ritchlin;André D. Beaulieu;Atul Deodhar;Richard Newmark;JingYuan Feng;Ngozi Erondu;Ajay Nirula The New England Journal of Medicine 2014,